Hematology

The CGTLive™ Hematology specialty topic page houses the most up-to-date clinical news coverage in the field of hematology gene and cell therapy. It also includes video interviews with key opinion leaders in the field of hematology/oncology about the latest relevant FDA actions, clinical guideline updates, and clinical trial findings related to the development of cell therapies, gene therapies, and engineered and regenerative medicines for various blood disorders.

Latest News

CGTLive®’s Weekly Rewind
CGTLive®’s Weekly Rewind – April 25, 2025

April 25th 2025

Review top news and interview highlights from the week ending April 25, 2025.

Around the Helix: Cell and Gene Therapy Company Updates – April 23, 2025
Around the Helix: Cell and Gene Therapy Company Updates – April 23, 2025

April 23rd 2025

Questions of Access: Gene Therapy’s Next Chapter in β-Thalassemia
Questions of Access: Gene Therapy’s Next Chapter in β-Thalassemia

April 21st 2025

Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Supporting Translational Cell Therapy Research

April 21st 2025

Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Barriers to Accessibility for CAR-T

April 20th 2025

Video Interviews
Podcasts
ImmunoLogic
ImmunoLogic
ImmunoLogic
ImmunoLogic
Latest CME Events & Activities

Upstate New York Hematology & Hematologic Oncology Conference: A Review of the 66th ASH Annual Meeting

April 26-27, 2025

Register Now!

29th Annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma

View More

Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy

View More

28th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma

View More

New Combination-Based Approaches to Newly Diagnosed MM: What Do the Data, the Experts, and Patients Say?

View More

Medical Crossfire®: Onco-Nurses Exchange Best Practices on PNH Treatment and Symptom Management Along the Patient Care Journey

View More

Show Me Your Care Plan™: How Can Onco-Nurses Improve Patient Care in CML Across the Treatment Continuum?

View More

Show Me Your Care Plan! Managing Breast Cancer Patients Under Current Data for Immuno- and Targeted Therapies, CDK4/6i, ADCs and Beyond

View More

New Combination-Based Approaches to NDMM: What Do the Data, the Experts, and Patients Say?

View More

Go To PER in Chicago

May 30, 2025 - June 3, 2025

Register Now!

Medical Crossfire™: Integrating Recent Evidence into the Treatment of Newly Diagnosed Multiple Myeloma

June 12, 2025

Register Now!

Broadening Horizons in Newly Diagnosed Multiple Myeloma—Exploring New Combination Approaches and Their Impact

View More

Medical Crossfire®: Risk-Adapted Management of Multiple Myeloma—How Do the Experts Do It?

View More

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

9th Annual Live Medical Crossfire®: Hematologic Malignancies

July 26, 2025

Register Now!

Exploring the Dynamic Shifts in the MDS Treatment Paradigm: Unveiling Advances in Disease Modifying Therapies, Spotlight on Cutting-Edge Clinical Trials, and the Latest Approvals

View More

Community Practice Connections™: Selecting and Sequencing Therapy for Patients with DLBCL in an Era of Expanding Options

View More

New Horizons in Multiple Myeloma Treatment – Selection and Sequencing From Newly Diagnosed to Relapsed/Refractory Disease

View More

BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for CSF-1R– Directed Treatment in Chronic GVHD

View More

Medical Crossfire®: Uncovering The Clinical Utility of Combination Therapies and MRD Assessment in Newly Diagnosed Multiple Myeloma

View More

Community Practice Connections™: 8th Annual School of Nursing Oncology™

View More

SimulatEd™: Patient-Centered Care to Improve Outcomes in Chronic Lymphocytic Leukemia

View More

(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

View More

(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

View More

Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

Addressing Pivotal Updates in AML – Expert Perspectives on Individualizing Management for Special Populations

View More

Innovations in MDS Care: Navigating New Treatment Paradigms, Breakthrough Therapies, and Emerging Clinical Evidence

View More

Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice

View More

Rounds with Dr Jabbour: Breaking Barriers in ALL Treatment

View More

How We Do It®: New Combinations Reshaping Treatment Decision-Making in Newly Diagnosed Multiple Myeloma

View More

More News

CGTLive®’s Weekly Rewind

CGTLive®’s Weekly Rewind – April 18, 2025

Noah Stansfield
April 18th 2025

Review top news and interview highlights from the week ending April 18, 2025.

Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center

Autologous Versus Allogeneic CAR-T for the Near-Term Future

Renier Brentjens, MD, PhD;Noah Stansfield
April 17th 2025

Renier Brentjens, MD, PhD, the chair of the department of medicine at Roswell Park Comprehensive Cancer Center, discussed his view on how the cell therapy field should proceed with regard to innovation.

Around the Helix: Cell and Gene Therapy Company Updates – April 16, 2025

Around the Helix: Cell and Gene Therapy Company Updates – April 16, 2025

Noah Stansfield
April 16th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center

Using Armored CAR T-Cells to Tackle Solid Tumors

Renier Brentjens, MD, PhD;Noah Stansfield
April 14th 2025

Renier Brentjens, MD, PhD, the chair of the department of medicine at Roswell Park Comprehensive Cancer Center, discussed the innovations necessary to make CAR-T therapy effective in solid tumor indications.

CGTLive®’s Weekly Rewind

CGTLive®’s Weekly Rewind – April 11, 2025

Noah Stansfield
April 11th 2025

Review top news and interview highlights from the week ending April 11, 2025.

Around the Helix: Cell and Gene Therapy Company Updates – April 9, 2025

Around the Helix: Cell and Gene Therapy Company Updates – April 9, 2025

Noah Stansfield
April 9th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

CGTLive®’s Weekly Rewind

CGTLive®’s Weekly Rewind – April 4, 2025

Noah Stansfield
April 4th 2025

Review top news and interview highlights from the week ending April 4, 2025.

Around the Helix: Cell and Gene Therapy Company Updates – April 2, 2025

Around the Helix: Cell and Gene Therapy Company Updates – April 2, 2025

Noah Stansfield
April 2nd 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

FDA Activity Recap: March 2025 Features FDA Approvals in Hemophilia, ATTR Amyloidosis, and More

FDA Activity Recap: March 2025 Features FDA Approvals in Hemophilia, ATTR Amyloidosis, and More

Noah Stansfield
April 1st 2025

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.

FDA Approves Sanofi’s siRNA Therapy Fitusiran for the Treatment of Hemophilia A and B

FDA Approves Sanofi’s siRNA Therapy Fitusiran for the Treatment of Hemophilia A and B

Noah Stansfield
March 31st 2025

The product is marketed under the name Qfitlia.

CGTLive®’s Weekly Rewind

CGTLive®’s Weekly Rewind – March 28, 2025

Noah Stansfield
March 28th 2025

Review top news and interview highlights from the week ending March 28, 2025.

Around the Helix: Cell and Gene Therapy Company Updates – March 26, 2025

Around the Helix: Cell and Gene Therapy Company Updates – March 26, 2025

Noah Stansfield
March 26th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

CGTLive®’s Weekly Rewind

CGTLive®’s Weekly Rewind – March 21, 2025

CGTLive Staff
March 21st 2025

Review top news and interview highlights from the week ending March 21, 2025.

FDA Approves Alnylam’s Vutrisiran for the Treatment of ATTR Amyloidosis With Cardiomyopathy

FDA Approves Alnylam’s Vutrisiran for the Treatment of ATTR Amyloidosis With Cardiomyopathy

Noah Stansfield
March 20th 2025

The product is marketed under the name Amvuttra.

Around the Helix: Cell and Gene Therapy Company Updates – March 19, 2025

Around the Helix: Cell and Gene Therapy Company Updates – March 19, 2025

Noah Stansfield
March 19th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Shanxi Bethune Hospital Evaluating CAR-T for R/R Hematological Tumors in Phase 2/3 Clinical Trial

Shanxi Bethune Hospital Evaluating CAR-T for R/R Hematological Tumors in Phase 2/3 Clinical Trial

Noah Stansfield
March 17th 2025

CGTLive® took a closer look at the single-center, open-label study, which aims to assess the safety and efficacy of the CAR-T therapy.

CGTLive®’s Weekly Rewind

CGTLive®’s Weekly Rewind – March 14, 2025

CGTLive Staff
March 14th 2025

Review top news and interview highlights from the week ending March 14, 2025.

Around the Helix: Cell and Gene Therapy Company Updates – March 12, 2025

Around the Helix: Cell and Gene Therapy Company Updates – March 12, 2025

Noah Stansfield
March 12th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

News and Expert Insights in Hemophilia Gene Therapy for Bleeding Disorders Awareness Month 2025

News and Expert Insights in Hemophilia Gene Therapy for Bleeding Disorders Awareness Month 2025

CGTLive Staff
March 9th 2025

In observance of Bleeding Disorders Awareness Month, held annually in March, catch up on some of the latest news and expert insights in gene therapy for hemophilia, which is among the most common of these disorders.

CGTLive®’s Weekly Rewind

CGTLive®’s Weekly Rewind – March 7, 2025

CGTLive Staff
March 7th 2025

Review top news and interview highlights from the week ending March 7, 2025.

Around the Helix: Cell and Gene Therapy Company Updates – March 5, 2025

Around the Helix: Cell and Gene Therapy Company Updates – March 5, 2025

Noah Stansfield
March 5th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

FDA Activity Recap: February 2025 Features Multiple BLA Acceptances, RMAT Designations, and More

FDA Activity Recap: February 2025 Features Multiple BLA Acceptances, RMAT Designations, and More

CGTLive Staff
March 2nd 2025

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.

CGTLive®’s Weekly Rewind

CGTLive®’s Weekly Rewind – February 28, 2025

CGTLive Staff
February 28th 2025

Review top news and interview highlights from the week ending February 28, 2025.

Around the Helix: Cell and Gene Therapy Company Updates – February 26, 2025

Around the Helix: Cell and Gene Therapy Company Updates – February 26, 2025

Noah Stansfield
February 26th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Alfred L. Garfall, MD, MS, the associate professor of medicine (hematology-oncology) and director of the Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program at the Hospital of the University of Pennsylvania

Ide-Cel and Lenalidomide Maintenance in MM Following Suboptimal ASCT Response

Alfred L. Garfall, MD, MS;Noah Stansfield
February 26th 2025

Alfred L. Garfall, MD, MS, discussed data from the phase 2 BMT CTN 1902 trial.

CGTLive®’s Weekly Rewind

CGTLive®’s Weekly Rewind – February 21, 2025

CGTLive Staff
February 21st 2025

Review top news and interview highlights from the week ending February 21, 2025.

Pfizer Jettisons FDA-Approved Hemophilia B Gene Therapy Beqvez

Pfizer Jettisons FDA-Approved Hemophilia B Gene Therapy Beqvez

Noah Stansfield
February 21st 2025

The company made the decision based on a lack of interest from the patient and clinician communities.

Nirav Shah, MD, an associate professor of medicine at Medical College of Wisconsin

Evaluating Zamto-Cel in R/R DLBCL

Nirav N. Shah, MD;Noah Stansfield
February 20th 2025

Nirav Shah, MD, an associate professor of medicine at Medical College of Wisconsin, discussed efficacy data presented at the 2025 Tandem Meetings.

Around the Helix: Cell and Gene Therapy Company Updates – February 19, 2025

Around the Helix: Cell and Gene Therapy Company Updates – February 19, 2025

Noah Stansfield
February 19th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center

Evaluating Poseida Therapeutics' P-BCMA-ALLO1 With Optimized Lymphodepletion in R/R Myeloma

Bhagirathbhai Dholaria, MBBS;Noah Stansfield
February 19th 2025

Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center, discussed new results presented at Tandem 2025.

12345678
...
55>
© 2025 MJH Life Sciences

All rights reserved.